{"id":5704,"date":"2024-05-02T09:19:26","date_gmt":"2024-05-02T14:19:26","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5704"},"modified":"2025-06-27T11:18:38","modified_gmt":"2025-06-27T16:18:38","slug":"nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/","title":{"rendered":"Nanoscope Therapeutics anuncia presentaciones en la reuni\u00f3n anual de ARVO"},"content":{"rendered":"
\n
\n
\n

<\/h1>\n<\/div>\n<\/div>\n<\/div>\n
\n
\n
\n
\n

DALLAS<\/span><\/span>,\u00a02 de mayo de 2024<\/span><\/span>\u00a0 \u2014 Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda cl\u00ednica en etapa avanzada que desarrolla terapias g\u00e9nicas para enfermedades degenerativas de la retina, anunci\u00f3 hoy que su plataforma de terapia g\u00e9nica Multi-Characteristic Opsin (MCO) se presentar\u00e1 en seis presentaciones en el\u00a0Reuni\u00f3n anual de ARVO<\/a>, teniendo lugar\u00a05 al 9 de mayo de 2024<\/span>\u00a0en\u00a0seattle<\/span>. El equipo directivo estar\u00e1 presente en la conferencia y disponible para reunirse en el stand #4620 de Nanoscope Therapeutics.<\/p>\n

Los detalles de las presentaciones son los siguientes:<\/p>\n

T\u00edtulo de presentaci\u00f3n:<\/b>\u00a0An\u00e1lisis longitudinal BCVA de la terapia optogen\u00e9tica independiente de la mutaci\u00f3n MCO-010 en dosis bajas o altas para la retinosis pigmentaria: resultados de 12 meses de una fase\u00a02b<\/span>\/3 ensayo cl\u00ednico aleatorizado, controlado de forma simulada, enmascarado por el paciente y el evaluador (RESTORE)
N\u00famero de presentaci\u00f3n:<\/b>\u00a02137
Tipo de presentaci\u00f3n:\u00a0<\/b>Sesi\u00f3n de art\u00edculos
T\u00edtulo de la sesi\u00f3n:<\/b>\u00a0Retinitis pigmentosa
Fecha de la sesi\u00f3n:<\/b>\u00a06 de mayo de 2024
Tiempo de sesi\u00f3n:<\/b>\u00a04:15 \u2013\u00a04:30 p.m. hora del Pac\u00edfico<\/span>
Ubicaci\u00f3n:<\/b>\u00a0612 \u2013\u00a0seattle<\/span>\u00a0Centro de convenciones \u2013 Edificio Arch
Presentador:<\/b>\u00a0Allen C. Ho, MD, asesor m\u00e9dico jefe<\/p>\n

T\u00edtulo del resumen:<\/b>\u00a0Concordancia test-retest del test de agudeza visual de Friburgo en visi\u00f3n ultrabaja
N\u00famero de resumen\/p\u00f3ster:<\/b>\u00a0A0223
Tipo de sesi\u00f3n:\u00a0<\/b>Sesi\u00f3n de carteles
T\u00edtulo de la sesi\u00f3n:<\/b>\u00a0Evaluaci\u00f3n del desempe\u00f1o de baja visi\u00f3n
Fecha de la sesi\u00f3n:<\/b>\u00a07 de mayo de 2024<\/span>
Tiempo de sesi\u00f3n:<\/b>\u00a01:15 \u2013\u00a03:00 p.m. hora del Pac\u00edfico<\/span>
Ubicaci\u00f3n:<\/b>\u00a0Sala de exposiciones \u2013\u00a0seattle<\/span>\u00a0centro de Convenciones
Presentador:<\/b>\u00a0Samuel Barone, MD, director m\u00e9dico<\/p>\n

T\u00edtulo del resumen:<\/b>\u00a0An\u00e1lisis longitudinal de BCVA de pacientes con enfermedad de Stargardt y degeneraci\u00f3n macular tratados con MCO-010, una terapia optogen\u00e9tica independiente de las mutaciones: resultados de 48 semanas de un ensayo cl\u00ednico de fase 2a (STARLIGHT)
N\u00famero de resumen\/p\u00f3ster:<\/b>\u00a0B0094
Tipo de sesi\u00f3n:\u00a0<\/b>Sesi\u00f3n de carteles
T\u00edtulo de la sesi\u00f3n:<\/b>\u00a0Oftalmolog\u00eda pedi\u00e1trica y enfermedades oculares hereditarias
Fecha de la sesi\u00f3n:<\/b>\u00a08 de mayo de 2024
Tiempo de sesi\u00f3n:<\/b>\u00a02:15 \u2013\u00a04:00 p.m. hora del Pac\u00edfico<\/span>
Ubicaci\u00f3n:<\/b>\u00a0Sala de exposiciones \u2013\u00a0seattle<\/span>\u00a0centro de Convenciones
Presentador:<\/b>\u00a0Vinit B. Mahajan, MD, PhD, Profesor de Oftalmolog\u00eda en\u00a0Universidad Stanford<\/span><\/p>\n

T\u00edtulo del resumen:<\/b>\u00a0La terapia g\u00e9nica con opsina multicaracter\u00edstica aten\u00faa la degeneraci\u00f3n de la retina y restaura la visi\u00f3n en modelos de rat\u00f3n con retinosis pigmentaria
N\u00famero de resumen\/p\u00f3ster:<\/b>\u00a0B0293
Tipo de sesi\u00f3n:\u00a0<\/b>Sesi\u00f3n de carteles
T\u00edtulo de la sesi\u00f3n:<\/b>\u00a0Terapias gen\u00e9ticas y celulares y otras terapias novedosas I
Fecha de la sesi\u00f3n:<\/b>\u00a08 de mayo de 2024
Tiempo de sesi\u00f3n:<\/b>\u00a02:15 \u2013\u00a04:00 p.m. hora del Pac\u00edfico<\/span>
Ubicaci\u00f3n:<\/b>\u00a0Sala de exposiciones \u2013\u00a0seattle<\/span>\u00a0centro de Convenciones
Presentador:<\/b>\u00a0Subrata Batabyal, PhD, Director, Desarrollo no cl\u00ednico<\/p>\n

T\u00edtulo del resumen:<\/b>\u00a0Caracterizaci\u00f3n de una opsina multicaracter\u00edstica activable por luz ambiental de banda ancha que respalda su rendimiento superior en la restauraci\u00f3n de la visi\u00f3n
N\u00famero de resumen\/p\u00f3ster:<\/b>\u00a0B0924
Tipo de sesi\u00f3n:\u00a0<\/b>Sesi\u00f3n de carteles
T\u00edtulo de la sesi\u00f3n:<\/b>\u00a0Terapias gen\u00e9ticas y celulares y otras terapias novedosas II
Fecha de la sesi\u00f3n:<\/b>\u00a09 de mayo de 2024
Tiempo de sesi\u00f3n:<\/b>\u00a08:00 \u2013\u00a09:45 a. m. hora del Pac\u00edfico<\/span>
Ubicaci\u00f3n:<\/b>\u00a0Sala de exposiciones \u2013\u00a0seattle<\/span>\u00a0centro de Convenciones
Presentador:<\/b>\u00a0Samarendra Mohanty, PhD, presidenta y directora cient\u00edfica<\/p>\n

T\u00edtulo del resumen:<\/b>\u00a0Eficacia in vivo de una nueva opsina multicaracter\u00edstica (MCO-010) en un modelo de rat\u00f3n con amaurosis cong\u00e9nita de Leber
N\u00famero de resumen\/p\u00f3ster:<\/b>\u00a0B0942
Tipo de sesi\u00f3n:\u00a0<\/b>Sesi\u00f3n de carteles
T\u00edtulo de la sesi\u00f3n:<\/b>\u00a0Terapias gen\u00e9ticas y celulares y otras terapias novedosas II
Fecha de la sesi\u00f3n:<\/b>\u00a09 de mayo de 2024
Tiempo de sesi\u00f3n:<\/b>\u00a08:00 \u2013\u00a09:45 a. m. hora del Pac\u00edfico<\/span>
Ubicaci\u00f3n:<\/b>\u00a0Sala de exposiciones \u2013\u00a0seattle<\/span>\u00a0centro de Convenciones
Presentador:<\/b>\u00a0Najam Sharif, PhD, DSc, vicepresidente de investigaci\u00f3n y desarrollo global<\/p>\n

Acerca de Nanoscope Therapeutics Inc.
<\/b>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas gen\u00e9ticamente independientes que restauran la vista para los millones de pacientes cegados por enfermedades hereditarias de la retina, para las cuales no existe cura. El principal activo de la empresa, MCO-010,\u00a0anunci\u00f3 recientemente los datos de 100 semanas de<\/a>\u00a0Fase de RESTAURACI\u00d3N\u00a02b<\/span>\/3 ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble enmascarado y controlado de forma simulada en los EE. UU. para la retinosis pigmentaria (NCT04945772<\/a>). La compa\u00f1\u00eda tambi\u00e9n complet\u00f3 recientemente el ensayo de fase 2 STARLIGHT de la terapia MCO-010 en pacientes con enfermedad de Stargardt (NCT05417126<\/a>). MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para la RP como para la enfermedad de Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para atrofias geogr\u00e1ficas secundarias a la degeneraci\u00f3n macular relacionada con la edad.<\/p>\n

Contacto de inversores:<\/b>
Socios Argot
212-600-1902
PR@nanostherapeutics.com<\/a><\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"

DALLAS,\u00a0May 2, 2024\u00a0 \u2014 Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases, today announced that its Multi-Characteristic Opsin (MCO) gene therapy platform will be featured in six presentations at the\u00a0ARVO Annual Meeting, taking place\u00a0May 5-9, 2024\u00a0in\u00a0Seattle. The management team will be present at the conference and available to […]<\/p>\n","protected":false},"author":6,"featured_media":5705,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5704","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-02T14:19:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T16:18:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ARVO_LI_2024._V2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2000\" \/>\n\t<meta property=\"og:image:height\" content=\"2000\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ARVO_LI_2024._V2.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/02\\\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/02\\\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting\",\"datePublished\":\"2024-05-02T14:19:26+00:00\",\"dateModified\":\"2025-06-27T16:18:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/02\\\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\\\/\"},\"wordCount\":567,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/02\\\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/NSCOPE_ARVO_LI_2024._V2.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/02\\\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/02\\\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\\\/\",\"name\":\"Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/02\\\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/02\\\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/NSCOPE_ARVO_LI_2024._V2.jpg\",\"datePublished\":\"2024-05-02T14:19:26+00:00\",\"dateModified\":\"2025-06-27T16:18:38+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/02\\\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/02\\\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/02\\\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/NSCOPE_ARVO_LI_2024._V2.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/NSCOPE_ARVO_LI_2024._V2.jpg\",\"width\":2000,\"height\":2000},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/02\\\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics anuncia presentaciones en la reuni\u00f3n anual de ARVO - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-05-02T14:19:26+00:00","article_modified_time":"2025-06-27T16:18:38+00:00","og_image":[{"width":2000,"height":2000,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ARVO_LI_2024._V2.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ARVO_LI_2024._V2.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting","datePublished":"2024-05-02T14:19:26+00:00","dateModified":"2025-06-27T16:18:38+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/"},"wordCount":567,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ARVO_LI_2024._V2.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/","url":"https:\/\/nanostherapeutics.com\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/","name":"Nanoscope Therapeutics anuncia presentaciones en la reuni\u00f3n anual de ARVO - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ARVO_LI_2024._V2.jpg","datePublished":"2024-05-02T14:19:26+00:00","dateModified":"2025-06-27T16:18:38+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ARVO_LI_2024._V2.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ARVO_LI_2024._V2.jpg","width":2000,"height":2000},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5704","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5704"}],"version-history":[{"count":2,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5704\/revisions"}],"predecessor-version":[{"id":9047,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5704\/revisions\/9047"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5705"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5704"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5704"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5704"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}